SPOTLIGHT -
Biologic approved for plaque psoriasis
NDA Sets Goal Date for Skin Infection Gel
If approved, berdazimer could be the first prescription product treat molluscum, a common skin infection caused by poxvirus. The Prescription Drug User Fee Act goal date is Jan. 5, 2024.
FDA Expands Cibinqo Label for Atopic Dermatitis in Adolescents
Cibinqo is an oral, once-daily JAK1 inhibitor now approved for those 12 years of age and older.
Express Scripts Adds Zoryve to National Formulary
Launched in August, Zoryve is a once-daily, steroid-free cream and is the first topical PDE4 inhibitor approved to treat plaque psoriasis in patients 12 years of age or older.
FDA Approves Duxipent for Rare Skin Disorder
Dupixent is the first treatment approved to treat prurigo nodularis, a chronic skin disorder characterized by the presence of hard, itchy nodules.
FDA Approves First Generic of Tazorac Gel
Commercial shipments are already under way of Cosette’s gel formulation of tazarotene to treat patients with acne and facial wrinkles.
FDA Approves First-in-Class Therapy for Psoriasis
Developed by Bristol Myers Squibb, Sotyktu is the first approved TYK2 inhibitor. It is expected to be available later this month.
